Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
CRWN 8 18037 0
NVAX 24 100942 7
RYL 23 535177 -5
LXP 20 100488 -2
As you can see these stocks had an average of 18.75 hedge funds with bullish positions and the average amount invested in these stocks was $189 million. That figure was $125 million in RES’s case. Novavax, Inc. (NASDAQ:NVAX) is the most popular stock in this table. On the other hand Crown Media Holdings, Inc (NASDAQ:CRWN) is the least popular one with only 8 bullish hedge fund positions. RPC, Inc. (NYSE:RES) is not the least popular stock in this group but hedge fund interest is still below average. This is a slightly negative signal and we’d rather spend our time researching stocks that hedge funds are piling on. In this regard NVAX might be a better candidate to consider a long position.
that idea has merit... if Novartis sees the handwriting on the wall.... they may well intend to jump into the novavax platform... I think they received 7 billion for their flu biz... just enough almost....to buy novavax
WHO and GAVI and FDA etc.. all should understand the need for a functional ebola vaccine for the people in these nations. I have to say... bats bodies are miniscule... where is the meat? Being bitten is another story...
you might check the number of shares, then vs now.... and the finances... the market cap now just might be a whole lot more...
"GAITHERSBURG, Md., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it has been awarded a grant of up to $89 million from the Bill & Melinda Gates Foundation to support development of the RSV F Vaccine Phase 3 clinical trial in pregnant women, planned to initiate during the first quarter of 2016. This grant will also support regulatory licensing efforts, providing a path to WHO prequalification. Upon licensure, Novavax has agreed to make the RSV F Vaccine affordable and accessible to people in the developing world."
This is a huge event for Novavax and RSV....
one would think they have expansion in mind.... and now that they have added the newly leased facility accross the street.. (around 6 months ago) I would believe that they'll be able to produce en mass when licensed with the Elderly RSV... and if called upon for H7N9 and Ebola vaccines (MERS too?) they'll be able to move quickly... This company's future is truly bright and on track. Let's hope that any buyout offer is refused and they continue to go it as an independent vaccine powerhouse.
first... the options manipulators are off our backs for another month after today. Both the vaccine conference in San Diego and the Stifel conference will be soaking into the investor brains. The 8 (9?) analysts will have updated their ratings and targets. The 40million shorted shares will take a long, scary look at the future and begin to cover. Even now, that figure many be significantly reduced. There are no expected impediments and positive news to expect over the coming months. Right now, the share price is indeed a gift. It's time to add shares as value increases back to the teens, perhaps sooner than later. There is an easy double in the coming 13 months... and, should a buyout occur... there will be more than a triple.
Thanksgiving will be all turkey, dressing, potatoes and gravy, cranberry... and rising share prices.
nonsense.... this is options week... and the strike at $7 is taking its toll. Big boys want the share price to hang out near $7.... This is obvious...
hopefully you may still meet your expectation... Next week we'll see $8+ for sure... after options week is gone and leaving no fowl oder... Stifel could come through with something for us... they need to assign an analyst, after Bucky's presentation.